Cannabinoids and Terpenes: What’s the Difference?

Last updated on August 12, 2026 · Originally published June 10, 2017

One group carries potency. The other carries much of the aroma. Inside the plant, their chemistry meets before it separates.

The difference between cannabinoids and terpenes is mostly structural. Phytocannabinoids are generally larger, far less volatile molecules; the aroma terpenes normally measured in cannabis are smaller, volatile molecules you can actually smell. But the two are more closely related than that split suggests — chemically, the major phytocannabinoids made by cannabis contain a terpene-derived component.

What actually separates a cannabinoid from a terpene?

Size is the most obvious difference, although molecular shape and functional groups matter too. THC has a molecular mass a little more than twice that of limonene. Together, those structural differences make limonene much more volatile: it escapes readily into the air, which is why you smell a jar of flower the moment you open it. THC does not, which is why THC itself has no smell.

Then there is what they do, and it is less uniform than the tidy version suggests. Cannabinoids interact with the body in several different ways. THC activates the CB1 and CB2 receptors directly, while CBD has little direct affinity for either and works through a broader, less direct set of targets. Most cannabis terpenes do not activate these receptors at all.

Numbers are worth a caveat too. The NIST reference library now holds 121 cannabinoid-related entries, though that count includes rare homologues, metabolites and degradation products rather than 121 compounds the plant reliably makes. More than 150 terpenes and terpenoids have been reported in cannabis. And terpenes are not unique to the plant — the same molecules show up in pine needles, citrus peel, lavender, and hops.

One clarification worth making, because the terms get used interchangeably and should not be: a terpene is a pure hydrocarbon, while a terpenoid has been chemically modified, usually by the addition of oxygen. Several compounds routinely listed as terpenes on a lab report — linalool, terpineol, borneol, nerolidol — are terpenoids in the strict sense. Our guide to the language of terpenes and terpenoids sorts the vocabulary out.

Are cannabinoids and terpenes actually related?

Far more than most explainers admit, and this is the part the usual comparison misses.

Both groups are produced mainly in the glandular trichomes of the flower, and cannabinoid biosynthesis intersects with one branch of terpene metabolism. Geranyl pyrophosphate, or GPP, is the precursor the plant uses to build monoterpenes. The plant also joins GPP to olivetolic acid to form CBGA, the central precursor to THCA, CBDA and CBCA.

THCA synthase then oxidatively cyclizes the geranyl portion of CBGA. In that precise sense, the major phytocannabinoids made by cannabis carry a terpene-derived fragment in their structure.

The qualifier matters. This is one branch meeting another, not a single origin for everything in the resin: sesquiterpenes like caryophyllene are built from a different precursor entirely, and the varin cannabinoids start from a related but distinct aromatic building block. Still, the point holds where it counts. The difference between cannabinoids and terpenes is not that they are two separate systems which happen to share a plant.

What do terpenes actually do?

Two jars of the same chemovar can smell noticeably different. That is largely the terpenes — fragrant, volatile compounds responsible for much of what reaches your nose, alongside sulfur compounds and other non-terpene volatiles that also shape cannabis aroma. Terpenes and cannabinoids both accumulate in the resin produced by glandular trichomes.

For the plant itself, aroma is not decoration. Terpenes can deter herbivores, attract predators and parasitoids of those herbivores, and contribute to protection against oxidative stress.

For the consumer, terpene profiles help distinguish products that look nearly identical on their potency labels. Whether they reliably explain differences in subjective effect is much less certain; minor cannabinoids, dose, inhalation pattern, expectation and individual biology may all contribute. Terpene content does vary considerably between plants, and even between harvests of the same chemovar, in a way that a potency percentage will never capture.

What terpene content does not reliably track is the old indica and sativa split. Those labels originated in botanical morphology and lineage, but modern retail usage is inconsistent enough that they are poor predictors of both chemistry and effect.

Nor does reducing each terpene to a single effect label solve the problem. Terpinolene is marketed relentlessly as the “energizing” terpene, yet when it was actually put to the test, it read as relaxing.

Does the entourage effect hold up?

This is where 2017’s confident answer has not aged well, so it is worth being precise.

The entourage effect proposes that cannabis compounds produce different results together than any one of them does alone. The term was coined in 1998 by Shimon Ben-Shabat, Raphael Mechoulam and colleagues, and it is worth knowing what it originally described: related lipids that appeared to enhance the endocannabinoid 2-AG. It was not a claim about terpenes amplifying THC. That broader version came later, and it has been repeated so often since that it is frequently treated as settled. It is not.

The strongest challenge came in 2019, when Australian researchers tested the six most common cannabis terpenes against human CB1 and CB2 receptors. None of them activated either receptor, and none changed how THC behaved at them. The paper was titled “Absence of Entourage”, and a separate group reached much the same conclusion the following year. Whatever terpenes are doing, they are mostly not doing it at the cannabinoid receptors.

Mostly, because there is a real exception. Beta-caryophyllene binds CB2 directly, which makes it a terpene that behaves like a cannabinoid and a neat illustration of how blurry this boundary gets.

Evidence has also accumulated on the other side. A 2021 University of Arizona study found that several terpenes produced cannabinoid-like behavioral effects in mice and were additive with a cannabinoid agonist, apparently through a mix of receptor pathways. And in 2024 a Johns Hopkins-led team ran the question in humans: twenty adults inhaled vaporized THC, D-limonene, both, or placebo across nine double-blind sessions. Limonene reduced THC-induced anxiety and paranoia in a dose-dependent way without systematically altering THC’s other effects or its blood levels.

That is a small trial, and it is one terpene against one outcome. But it is direct human evidence that a terpene can change how a cannabinoid feels. A 2024 systematic review landed roughly where the field is now: individual interactions are real and worth studying, while the broad claim that everything in the plant synergizes with everything else remains unproven.

The useful version is narrower than the marketing version. Specific compounds, specific pairings, specific outcomes.

Why are the two usually tested differently?

Because of a difference that trips up more people than any other: in fresh flower, THC and CBD occur predominantly as their acidic precursors, THCA and CBDA, although some neutral cannabinoids may already be present. Heat converts them, which is why decarboxylation is its own step with its own losses.

Terpenes have no equivalent acid form. Heat does not convert them into an active version — it drives them off and may also degrade or transform them, which is why the same drying, curing, and extraction choices that preserve potency can strip aroma.

This is why laboratories generally use separate methods for the two groups. Terpenes are commonly analysed by gas chromatography, since they are volatile enough to vaporize cleanly; potency testing is generally performed by liquid chromatography, which avoids decarboxylating the acids mid-run and blurring THCA and THC into a single number. Simultaneous methods do exist — researchers have published a gas-chromatographic method covering both, and a two-dimensional liquid-chromatography approach followed in 2024 — but accommodating compounds with such different volatility and polarity makes them considerably more complicated than routine compliance work requires. How labs test for terpenes remains a different problem from testing for potency, and the instruments reflect it.

Boiling-point charts circulate widely as a shortcut here, and most of them do not hold up to scrutiny.

What this means when you are choosing cannabis

Better testing has made it possible to shop on more than a THC percentage. Terpene profiles now appear on menus and certificates of analysis, and you can choose by aroma, cannabinoid content, or the combination of the two.

Aroma and flavor are solid ground for that choice. Predicting a specific effect from a terpene profile is not — that remains speculative, whatever the menu copy implies.

Which is close to what this article predicted in 2017, and it has largely come true: terpene-forward menus are now normal in mature markets. What has changed is the reason to care. It is not that terpenes secretly amplify everything. It is that they vary far more between products than potency numbers suggest, and they are the part of the label nobody is optimizing for you.

For a fuller tour of the individual compounds, their aromas, and what the research says about each, start with our complete guide to cannabis terpenes.

Originally published June 10, 2017. Updated August 12, 2026 to correct the description of terpenes as flavonoids, replace the indica/sativa effects framing, rewrite the entourage-effect section against the 2019–2024 literature, add the shared biosynthetic origin of cannabinoids and terpenes, and clarify why the two groups are usually measured by different analytical methods.

Reviewed by Nani Frenkel, chief editor.

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.